Most biotech teams assume GMP readiness begins when a product enters clinical phases. In reality, the foundations of GMP are built much earlier, during drug development, often without being explicitly labeled as such.
Drug Development Decisions That Quietly Define GMP Success
During early drug development, teams focus on speed, proof of concept, and technical feasibility. However, several “invisible” decisions made at this stage have long-term GMP implications.
For example:
- Selecting raw materials without considering GMP-grade availability
- Developing analytical methods that are not scalable or transferable
- Optimizing processes under conditions that cannot be reproduced at larger scale
- Using cell lines or constructs that introduce regulatory complexity later
These decisions are rarely revisited until the program approaches clinical phases, at which point changes become costly and time-consuming.
At 53Biologics, our Process Development Services (microbial and mammalian) are designed to anticipate these downstream constraints early, aligning development work with future GMP expectations.
GMP Is Not a Phase, It Is a System That Must Be Built Gradually
One of the most misleading ideas in biologics manufacturing is treating GMP as a switch that can be turned on when entering clinical phases.
In reality, GMP is a system composed of: process understanding, documentation practices, material traceability and quality risk management. These elements cannot be implemented overnight. They must evolve alongside the process itself.
According to international standards such as those from the World Health Organization (WHO), consistency and control are demonstrated over time, not created at a single milestone.
This is why GMP readiness must begin during drug development, even if full GMP manufacturing is not yet required.
The Hidden Cost of Late GMP Alignment
When GMP considerations are postponed until clinical phases, companies often face unexpected challenges:
- Re-development of upstream or downstream processes
- Re-validation of analytical methods
- Delays in technology transfer
- Increased regulatory scrutiny
These issues are not caused by poor science, but by a lack of early alignment between development and GMP requirements.
At 53Biologics, our GMP Manufacturing Services for microbial and mammalian are closely integrated with development activities, ensuring that processes evolve with compliance in mind rather than being retrofitted later.
Clinical Phases Do Not Create Robust Processes, They Expose Them
A novel way to think about this transition is to view clinical phases not as the start of GMP, but as a stress test of everything built during drug development.
Clinical manufacturing reveals: process variability that was not previously visible, weaknesses in control strategies, gaps in documentation or traceability and scalability limitations. If GMP readiness has not been embedded earlier, these issues surface when timelines are least flexible.
This is why leading biotech companies increasingly involve a CDMO before clinical phases, using development as a preparation stage rather than a separate phase.
How to Build GMP Readiness During Drug Development
For decision-stage companies, the goal is not to fully implement GMP during drug development, but to build a GMP-compatible process.
This involves:
- Selecting materials with future GMP compatibility
Avoiding components that will require replacement later - Designing scalable processes from the beginning
Ensuring parameters can be translated to larger volumes - Developing transferable analytical methods
Methods should be robust and adaptable to GMP environments - Documenting with intent, not just necessity
Creating records that can support future regulatory requirements - Engaging a CDMO early in the process
Bringing GMP expertise into development decisions
At 53Biologics, we integrate these principles into our Biologics Production approach, helping clients move toward clinical manufacturing without disruptive changes.
A Shift in Mindset: From “When to Start GMP” to “How Early to Think GMP”
The most important shift is conceptual. Instead of asking when GMP starts, companies should ask how early GMP thinking should be integrated into drug development.
The answer is simple: as early as decisions begin to affect scalability, reproducibility, and regulatory acceptance.
This does not mean slowing development. It means making smarter decisions that prevent future delays.
About 53Biologics:
53Biologics is a Spanish CDMO specialized in decoding biologics production, from DNA to proteins. The company provide services from preclinical development to GMP manufacturing, supporting their clients in getting their biological products to market as quickly as possible.
For more information or to speak with one of our experts email us at [email protected]
